ArticleNature biomedical engineering2026
Label-free navigation system for grading prostate tumour malignancy in situ via tissue pH and prostate-specific antigen activity.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A selection pipeline for switchable aptamer beacons in broad-spectrum protein detection.Nature biomedical engineering · 2026Article
- Article
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
- Machine-Learning-Enabled Raman Spectroscopy Refines Indocyanine Green Fluorescence Boundaries for Precise Glioblastoma Margin Delineation.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Radical prostatectomy is a standard curative approach for high-risk prostate cancer, yet accurately defining tumour margins during surgery remains a major challenge. Intraoperative assessment of prostate tumour malignancy-particularly those with high aggressiveness catalogued in Gleason grade group (GG) ≥ 3-is crucial to prevent positive surgical margins and minimize postoperative complications. Here we develop a surface-enhanced Raman scattering (SERS)-based navigation system for intraoperative localization of high-grade malignant regions by simultaneously accessing tissue acidity and prostate-specific antigen (PSA) enzymatic activity. This system integrates a sampling pen for automated biomarker extraction from tissue surfaces, a nano-imprinted SERS array producing a ratiometric Raman signal in response to acidity and PSA activity, and a two-dimensional deep-learning model for rapid Raman spectral interpretation. We show that the system can intraoperatively identify GG ≥ 3 malignancies in fresh prostate tissues from 144 Chinese patients with an area under the receiver operating characteristic curve of 0.89. This SERS-based navigation system holds strong potential to enhance surgical precision, minimize tumour residue and ultimately improve patient outcomes.
Indexed as
Identifiers
41254130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.